Depakin vs. Vigabatrin: What are the differences in treating spasticity in children?

The main component of Depakin is sodium valproate, which is an anti-epileptic drug that reduces epileptic seizures by inhibiting neuronal activity. It mainly acts on generalized and partial-onset epilepsy. Depakine can increase the concentration of the inhibitory neurotransmitter GABA in the brain, thereby reducing the excitability of neurons.

Vibatrin is vigabatrin, and its mechanism of action is to increase the concentration of GABA in the brain by irreversibly inhibiting GABA aminotransferase. GABA is an important inhibitory neurotransmitter in the central nervous system. It plays a key role in controlling the excessive excitability of neurons.

Debajin is effective in treating generalized epilepsy and can effectively control symptoms caused by epilepsy, such as twitching of limbs, foaming at the mouth, and disturbance of consciousness. For partial-onset epilepsy, results may vary among individuals.

Vigabatrin is particularly indicated for the treatment of drug-resistant partial-onset epilepsy, especially nodding epilepsy and myoclonic epilepsy in children. In addition, Vigabatrin has also shown certain efficacy in the treatment of infantile spasms and can be used as an auxiliary treatment.

Possible side effects of Depakin include drowsiness, loss of appetite, weight gain, abnormal behavior, and cognitive decline. Long-term use may also cause damage to the liver, so liver function and other indicators need to be monitored regularly.

Common side effects of Vigabatrin include fatigue, drowsiness, headache, diplopia, etc. Some more serious side effects may also occur, such as visual field defects, retinopathy, etc. In addition, Vigabatrin may lead to risks such as anemia and increased suicidal ideation, and patients' physical condition and emotional changes need to be closely monitored.